CUPERTINO, Calif., Jul 11, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that the initial purchaser of $50 million of its 6.25% Convertible Notes due 2008 has elected to exercise its option to purchase an additional $10 million principal amount of such Notes. As a result, the final aggregate principal amount of […]
CUPERTINO, Calif., June 13 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it agreed to privately place $50 million aggregate principal amount of Convertible Notes due 2008. These Notes will be convertible into DURECT Corporation common stock at a conversion price of $3.15 per share (reflecting a premium of 25%, relative to the NASDAQ
DURECT Corporation Announces Pricing of $50 Million Convertible Note Offering Read More »
CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it proposes to offer a new issue of $50 million of Convertible Notes due 2008 through a Rule 144A offering to qualified institutional buyers. These notes will be convertible into DURECT common stock at a price to be determined. The Company has
DURECT Corporation Announces Proposed $50 Million Convertible Debt Offering Read More »
CUPERTINO, Calif., June 10 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the Company has commenced clinical testing of its post-operative pain relief depot product. DURECT’s post-operative pain relief depot product, a sustained release injectible using the SABER(TM) delivery system and a local anesthetic, is designed to be administered locally around a surgical site
CUPERTINO, Calif., May 15, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Friedman Billings Ramsey 7th Annual Technology & Growth Investor Conference. The conference is being held at The Millennium Hotel in New York City. James E. Brown, DVM, Chief Executive Officer, will be presenting at
CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2003. DURECT’s net loss for the three months ended March 31, 2003 was $5.9 million or 12 cents per share, compared to $9.7 million or 20 cents per share for the same period in
DURECT Corporation Announces First Quarter 2003 Financial Results Read More »
CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. The conference is being held at The Millennium Hotel in New York City. James E. Brown, DVM, Chief Executive Officer, will be presenting at the conference on Wednesday, April 30,
CUPERTINO, Calif., April 15 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, April 28, 2003 at 4:30 p.m. EST with Jim Brown, President and Chief Executive Officer, Tom
DURECT Corporation Invites You to Join Its First Quarter 2003 Conference Call on the Web Read More »
CUPERTINO, Calif., Jan. 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2002. DURECT’s net loss for the three months ended December 31, 2002 was $8.5 million or 17 cents per share, compared to $10.1 million or 21 cents per share for the same
DURECT Corporation Reports Fourth Quarter 2002 and Year End Financial Results Read More »
CUPERTINO, Calif., Jan. 15 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter and year end 2002 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, January 28, 2003 at 4:30 p.m. EST with Jim Brown, President and Chief
